Zydus Lifesciences (ZYDUSLIFE) — Financial Results

Zydus Lifesciences reported consolidated revenue of ₹52.7 billion (up 17% YoY), EBITDA of ₹13.9 billion (up 26% YoY), and net profit of ₹10.2 billion (up 30% YoY) for Q3 FY25, driven by US formulation growth, India's 8% secondary sales increase, and international demand. Key developments include FDA approvals, clinical progress for ALS drug Usnoflast, and acquisition of Natural (India) Pvt. Ltd. Management highlighted sustained growth momentum for FY25 amid strategic pipeline expansion and international market entry.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ZYDUSLIFE ✨ Ask AI About This

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

💡 Ask AI about this filing

"How does this financial results affect Zydus Lifesciences Limited's outlook?" "What did Zydus Lifesciences Limited announce on 11 February 2025?" "Is this positive or negative for ZYDUSLIFE?"

Ask AI Free →

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

🔥 Also filed on 11 February 2025

VEDL Vedanta Limited Corporate Action WIPRO Wipro Limited Corporate Action AXISBANK Axis Bank Limited Corporate Action BRITANNIA Britannia Industries Limited Financial Results DELHIVERY Delhivery Limited Corporate Action EICHERMOT Eicher Motors Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.